Sweden · Delayed Price · Currency is SEK Senzime AB Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 90% in constant currencies for 2025, with Q4 revenues more than doubling year-over-year. Gross margin and EBITDA improved, while operating expenses remained stable. Positive cash flow is targeted for Q4 2026, supported by strong global growth and new product launches.
-
A highly accurate nerve monitoring system is transforming anesthesia safety and cost efficiency, with rapid adoption in the U.S. and other key markets. Regulatory guidelines and industry partnerships are fueling growth, though challenges remain with tariffs and hospital procurement cycles.
-
Achieved 80% growth in constant currencies and 70% sales growth year-over-year, with strong U.S. and Asian market performance. Gross margin improved despite currency and tariff headwinds, and major hospital contracts and new partnerships support continued expansion.
-
A paradigm shift in anesthesia monitoring is underway, driven by new guidelines and highly accurate electromyography technology. Rapid adoption, strong recurring revenue, and global partnerships are fueling hyper-growth, with profitability targeted by 2027.
-
Sales surged 90% in local currencies for H1 2025, with strong U.S. growth and stable margins despite tariff and currency headwinds. SEK 110.4 million was raised in a share issue, supporting expansion and positive cash flow targets.
-
Net sales surged 94% year-over-year, driven by next-gen product launches and strong global demand, with gross margin improvement and flat operating expenses. The company is on track with its financial targets, expanding in the U.S., Europe, and Asia, and securing financing to reach profitability.
Fiscal Year 2024
-
Achieved 65% sales growth in 2024, led by the U.S. and strong recurring sensor sales. Launched next-gen TetraGraph, driving future growth despite a Q4 sales dip. 2025 guidance targets over 100% revenue growth, with robust cash position and expanding global partnerships.
-
Q3 sales surged 90% year-over-year to SEK 17.4 million, led by strong U.S. and Asia growth and increased sensor utilization. Gross margin softened due to lower monitor prices, but next-gen product launch and SEK 86 million capital raise support positive long-term outlook.
-
Q2 saw 76% sales growth and major U.S. expansion, with 40 new hospital accounts and strong sensor shipments. Gross margin dipped due to product mix and one-time costs, but long-term targets remain intact. U.S. market drives growth, while Europe lags.